Jefferies Maintains Buy on Insulet, Lowers Price Target to $190
Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $275 to $190.
Share
Why It Matters
A big stock watcher still thinks Insulet is good to own. But they think the stock might be worth less money right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.